Warren Buffett’s conglomerate discloses positions in UnitedHealth, Nucor, D.R. Horton, Lamar Advertising, and Allegion
Berkshire Hathaway (BRK.A, BRK.B) has revealed new equity positions in a diverse group of companies spanning healthcare, industrials, homebuilding, advertising, and security solutions. The investments were disclosed in the firm’s latest regulatory filing, offering insight into the portfolio moves of Warren Buffett’s closely watched conglomerate.
The largest of the new stakes is in UnitedHealth Group Inc. (NYSE: UNH), with Berkshire acquiring 3,084,664 shares. UnitedHealth is a leading U.S. health insurance and healthcare services provider, and the investment reflects continued interest in the defensive, cash-generating healthcare sector.
In the industrial space, Berkshire initiated a position in steelmaker Nucor Corp. (NUE), purchasing 6,614,112 shares. Nucor, the largest steel producer in the United States, stands to benefit from infrastructure spending and robust demand in construction and manufacturing.
The firm also took a position in homebuilder D.R. Horton Inc. (DHI), acquiring 1,485,350 shares. The move signals confidence in the long-term U.S. housing market, despite current headwinds from elevated interest rates.
In real estate and media, Berkshire invested in Lamar Advertising Co. (LAMR), purchasing 1,169,507 shares. Lamar is one of the largest outdoor advertising companies in North America, with a portfolio of billboards and digital displays across the U.S.
Rounding out the new positions, Berkshire acquired 780,133 shares of Allegion Plc (ALLE), a global provider of security products such as locks, doors, and access control systems.
While the exact rationale for each investment remains undisclosed, the mix of sectors highlights Berkshire Hathaway’s diversified approach and focus on companies with strong market positions and long-term growth potential. Investors will be watching closely to see if these stakes are expanded in the quarters ahead.
You might like this article:Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development
